Millennium Management LLC Grows Position in VBI Vaccines Inc (VBIV)

Share on StockTwits

Millennium Management LLC increased its stake in shares of VBI Vaccines Inc (NASDAQ:VBIV) by 118.7% during the second quarter, Holdings Channel reports. The institutional investor owned 531,117 shares of the biopharmaceutical company’s stock after acquiring an additional 288,214 shares during the period. Millennium Management LLC’s holdings in VBI Vaccines were worth $1,461,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Paloma Partners Management Co purchased a new position in shares of VBI Vaccines during the second quarter worth about $254,000. Altshuler Shaham Ltd grew its holdings in shares of VBI Vaccines by 11.5% during the second quarter. Altshuler Shaham Ltd now owns 891,442 shares of the biopharmaceutical company’s stock worth $2,452,000 after buying an additional 91,800 shares during the last quarter. Alpine Global Management LLC purchased a new position in shares of VBI Vaccines during the second quarter worth about $222,000. Menora Mivtachim Holdings LTD. grew its holdings in shares of VBI Vaccines by 27.4% during the second quarter. Menora Mivtachim Holdings LTD. now owns 3,459,868 shares of the biopharmaceutical company’s stock worth $9,515,000 after buying an additional 744,706 shares during the last quarter. Finally, DRW Securities LLC purchased a new position in shares of VBI Vaccines during the second quarter worth about $126,000. 48.00% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ VBIV opened at $1.73 on Thursday. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 0.14. VBI Vaccines Inc has a 52-week low of $1.64 and a 52-week high of $5.10.

A number of equities analysts recently issued reports on the company. Zacks Investment Research lowered VBI Vaccines from a “hold” rating to a “sell” rating in a report on Friday, September 28th. BMO Capital Markets lowered their price target on VBI Vaccines from $13.00 to $12.00 and set an “outperform” rating on the stock in a report on Friday, July 27th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. VBI Vaccines has an average rating of “Hold” and a consensus target price of $9.08.

In other news, CEO Jeff Baxter acquired 13,500 shares of VBI Vaccines stock in a transaction that occurred on Friday, August 3rd. The stock was purchased at an average price of $2.01 per share, for a total transaction of $27,135.00. Following the completion of the transaction, the chief executive officer now directly owns 224,905 shares in the company, valued at $452,059.05. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders have purchased 23,600 shares of company stock worth $46,788. Corporate insiders own 16.20% of the company’s stock.

VBI Vaccines Profile

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus.

See Also: What is dollar cost averaging (DCA)?

Want to see what other hedge funds are holding VBIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VBI Vaccines Inc (NASDAQ:VBIV).

Institutional Ownership by Quarter for VBI Vaccines (NASDAQ:VBIV)

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply